Literature DB >> 2557535

Inhibition of epidermal growth factor receptor tyrosine kinase activity in A431 human epidermoid cells following psoralen/ultraviolet light treatment.

F H Mermelstein1, T F Abidi, J D Laskin.   

Abstract

One of the more prominent clinical treatments for skin diseases such as psoriasis and vitiligo involves the use of a combination of psoralens and UV light, a procedure referred to as PUVA chemotherapy. This drug regimen markedly alters epidermal cell growth and differentiation. In many cell types, an early cellular event following treatment of cells with PUVA is inhibition of binding of epidermal growth factor (EGF) to its receptor. To examine the mechanism underlying this effect, we used A431 cells, a human epidermal cell line known to express large numbers of EGF receptors. We found that exposure of A431 cells to PUVA caused a dramatic inhibition of EGF-stimulated EGF receptor tyrosine kinase activity. Inhibition required intact cells and did not appear to be mediated by protein kinase C, because this inhibition was apparent in cells in which the enzyme was down-regulated by phorbol ester pretreatment and in cells treated with inhibitors of protein kinase C. Inhibition of tyrosine kinase activity by PUVA was distinct from other inhibitors of EGF receptor function in that it was associated with a rapid increase in the amount of phosphate incorporated into serine residues of the EGF receptor. This suggested that PUVA-induced serine phosphorylation may mediate EGF receptor kinase activity. These results demonstrate that alterations in EGF receptor function may contribute to the therapeutic efficacy of PUVA in photo-chemotherapy.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2557535

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  8 in total

1.  Cyclosporin A, FK506 and dithranol after tyrosine-specific protein phosphorylation in HaCaT keratinocytes.

Authors:  H M Ockenfels; G Nussbaum; T Schultewolter; P M Burger; M Goos
Journal:  Arch Dermatol Res       Date:  1995       Impact factor: 3.017

2.  EGF receptor expression and growth of psoriatic and normal human keratinocytes are modulated by 1.25 (OH)2-vitamin D3 ex vivo.

Authors:  A M Boisseau-Garsaud; P Donatien; C Margerin; A Taïeb
Journal:  Arch Dermatol Res       Date:  1996-07       Impact factor: 3.017

3.  Rapid uptake of tyrphostin into A431 human epidermoid cells is followed by delayed inhibition of epidermal growth factor (EGF)-stimulated EGF receptor tyrosine kinase activity.

Authors:  C A Faaland; F H Mermelstein; J Hayashi; J D Laskin
Journal:  Mol Cell Biol       Date:  1991-05       Impact factor: 4.272

4.  Production of hydrogen peroxide by cutaneous T-cell lymphoma following photopheresis with psoralens and ultraviolet light.

Authors:  D E Heck; E Bisaccia; S Armus; J D Laskin
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

5.  Psoralen Derivatives with Enhanced Potency.

Authors:  Alexandru D Buhimschi; David M Gooden; Hongwu Jing; Diane R Fels; Katherine S Hansen; Wayne F Beyer; Mark W Dewhirst; Harold Walder; Francis P Gasparro
Journal:  Photochem Photobiol       Date:  2020-06-24       Impact factor: 3.421

6.  Mechanism of action of psoralens: isobologram analysis reveals that ultraviolet light potentiation of psoralen action is not additive but synergistic.

Authors:  E J Yurkow; J D Laskin
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

7.  Molecular Mechanisms of UV-Induced Apoptosis and Its Effects on Skin Residential Cells: The Implication in UV-Based Phototherapy.

Authors:  Chih-Hung Lee; Shi-Bei Wu; Chien-Hui Hong; Hsin-Su Yu; Yau-Huei Wei
Journal:  Int J Mol Sci       Date:  2013-03-20       Impact factor: 5.923

8.  Photo-activated psoralen binds the ErbB2 catalytic kinase domain, blocking ErbB2 signaling and triggering tumor cell apoptosis.

Authors:  Wenle Xia; David Gooden; Leihua Liu; Sumin Zhao; Erik J Soderblom; Eric J Toone; Wayne F Beyer; Harold Walder; Neil L Spector
Journal:  PLoS One       Date:  2014-02-14       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.